Major Depressive Disorder
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Protein-binding biomarker may indicate stress-related increase in suicidal ideation
Presence of a protein-binding biomarker in a small cohort of adults with depression may be an indicator that suicidal ideation increases because of elevated stress, according to research from JAMA Psychiatry.
Dementia risk factors, new depression therapy: Here are the top psych stories of 2024
At the Alzheimer's Association International Conference, the Lancet Commission unveiled two new modifiable risk factors for dementia: high cholesterol and vision loss.
White matter alterations in brain strongly associated with cognitive impairment
Alterations in white matter integrity were linked to cognitive impairment, and associations were strongest in those with major depressive disorder compared with healthy controls, according to new research.
High-dose psilocybin may help treat depressive symptoms, with small effect size
High-dose psilocybin showed the potential to treat depressive symptoms, although the effect size appeared small and comparable to that of escitalopram, according to results of a network meta-analysis published in The BMJ.
Dermatologists play significant role in detecting, addressing body dysmorphic disorder
In a new study published in the Journal of Drugs in Dermatology, researchers discussed how and why dermatologists have a significant role to play in the diagnosing and addressing of body dysmorphic disorder.
VIDEO: ‘New hope on the horizon’ in psychedelic medicine
NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.
J&J seeks FDA approval of esketamine as monotherapy for treatment-resistant depression
Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.
FDA grants expanded indication for Deep TMS for treatment of depression in older adults
The FDA has granted an expanded indication for BrainsWay’s Deep Transcranial Magnetic Stimulation system for depression treatment in patients aged 22 to 86 years, according to a company press release.
'A wild west': Patients seek new depression treatments with different mechanisms of action
Patients have become increasingly disillusioned with traditional depression treatments, and the search for new therapies has created some chaos in the field, according to experts.